Acknowledgements
DISEASE
This work was supported by Guangdong Provincial Key Laboratory of Human Disease Genomics (2020B1212070028), National Natural Science Foundation of China (82241013), the Science and Technology Commission of Shanghai Municipality (20ZR1411600), Shanghai Hospital Development Center (SHDC2020CR4039). Adebrelimab used in this clinical trial was supported by Hengrui Pharmaceuticals Co. Ltd, China. We thank China National GeneBank for their support on the sequencing services and data storage. We also thank F. Li for his guidance on bioinformatic analysis and statistical analysis.